Cargando…
Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
BACKGROUND: Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammati...
Autores principales: | Coufal, Stepan, Kverka, Miloslav, Kreisinger, Jakub, Thon, Tomas, Rob, Filip, Kolar, Martin, Reiss, Zuzana, Schierova, Dagmar, Kostovcikova, Klara, Roubalova, Radka, Bajer, Lukas, Jackova, Zuzana, Mihula, Martin, Drastich, Pavel, Tresnak Hercogova, Jana, Novakova, Michaela, Vasatko, Martin, Lukas, Milan, Tlaskalova-Hogenova, Helena, Jiraskova Zakostelska, Zuzana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299888/ https://www.ncbi.nlm.nih.gov/pubmed/37383609 http://dx.doi.org/10.1155/2023/1535484 |
Ejemplares similares
-
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study
por: Rob, Filip, et al.
Publicado: (2022) -
Skin microbiota signature distinguishes IBD patients and reflects skin adverse events during anti-TNF therapy
por: Reiss, Zuzana, et al.
Publicado: (2023) -
Fecal Microbiome Changes and Specific Anti-Bacterial Response in Patients with IBD during Anti-TNF Therapy
por: Schierova, Dagmar, et al.
Publicado: (2021) -
Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response
por: Coufal, Stepan, et al.
Publicado: (2019) -
Oral Microbiota Composition and Antimicrobial Antibody Response in Patients with Recurrent Aphthous Stomatitis
por: Stehlikova, Zuzana, et al.
Publicado: (2019)